Skip to main content
2024 Guide to Patient Support Services

Pharmacyclics & Janssen Biotech

2024 PSS Guide

Pharmacyclics and Janssen Biotech: Imbruvica By Your Side Patient Support Program

Imbruvica By Your Side Patient
Dose Exchange Program

Pharmacyclics and Janssen Biotech offer the Imbruvica By Your Side patient support program to assist patients while taking Imbruvica (Table). This program offers personalized support to help patients access and stay on track with Imbruvica, including:

  • Comprehensive resources individually selected for your patients
  • Financial guidance for commercially, federally, or uninsured patients
  • Imbruvica By Your Side Nurse Ambassadors who provide one-on-one guidance
  • Dose Exchange Program.

To learn more or to enroll your patient in the Imbruvica By Your Side patient support program, call 888-968-7743 or visit Imbruvica By Your Side.

Affording Treatment

Imbruvica By Your Side Nurse Ambassadors connect your patients with insurance specialists to learn about access to Imbruvica and find affordability support options. Eligible patients with commercial insurance may be able to pay as little as $0 per prescription of Imbruvica.

For uninsured patients, the Janssen-affiliated Johnson & Johnson Patient Assistance Foundation, which is an independent, nonprofit organization, may offer assistance with accessing Imbruvica for eligible patients who qualify based on financial need. You can check eligibility at

For patients with federally funded Medicare, Medicaid, or commercial insurance, financial assistance may be available from independent charitable organizations.

Dose Exchange Program

This program facilitates a dose reduction if you decide to adjust your patient’s dose before they have finished their current pack of Imbruvica.

To learn more or to enroll your patient in the Dose Exchange Program, visit Dose Exchange Program.

TABLE Pharmacyclics Oncology Drug

Patient support programs

Imbruvica (ibrutinib)
Treatment of adults with chronic lymphocytic leukemia (CLL) or with small lymphocytic lymphoma (SLL), including CLL or SLL with 17p deletion; adults with Waldenström macroglobulinemia; and adults and pediatric patients age ≥1 year with chronic graft-versus-host disease, after failure of ≥1 lines of systemic therapy
Patient support programs